CRISPR Therapeutics Announces Positive Phase 1 Clinical

-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025-

-Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in circulating ANGPTL3 with a mean reduction…